Assessment of lymph nodes and prostate status with early dynamic curves PET/CT 18F-choline in prostate cancer

被引:2
|
作者
Mathieu, C. [1 ]
Ferrer, L. [2 ,3 ]
Carlier, T. [2 ,4 ]
Colombie, M. [1 ]
Rusu, D. [1 ]
Kraeber-Bodere, F. [1 ,2 ,4 ]
Campion, L. [2 ,5 ]
Rousseau, C. [1 ,2 ]
机构
[1] ICO Rene Gauducheau, Serv Med Nucl, F-44805 St Herblain, France
[2] INSERM, CRCNA, UMR 892, CNRS UMR 6299, F-44007 Nantes 1, France
[3] ICO Rene Gauducheau, Serv Phys Med, F-44805 St Herblain, France
[4] CHU Nantes, Serv Med Nucl, F-44093 Nantes, France
[5] ICO Rene Gauducheau, Serv Biostast, F-44805 St Herblain, France
来源
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2015年 / 39卷 / 02期
关键词
F-18-choline; Prostate cancer; Dynamic curves; Early acquisition; MRI; LOCALIZATION; RELAPSE; RISK;
D O I
10.1016/j.mednuc.2015.01.006
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aim. - Analyse early dynamic F-18-Choline (FCH) PET/CT acquisitions to define lymph nodes and prostate pathological status. Patients and methods. - Retrospective analysis was performed on 39 patients for initial staging (n = 18) or after initial treatment (n = 21). Patients underwent 10 minutes dynamic acquisitions centered on pelvis, after injection of 3-4 MBq/kg of FCH. Whole body images were performed about 1 hour after injection and were acquired on PET/CT GE Discovery LS (GE-LS) or Siemens Biograph mCT (mCT). Maximum SUVaccording to time was measured on lymph nodes and prostate lesions. The status of each lesion was based on histological results or patient follow-up (> 6 months). Results. - The median PSA was 8.46 ng/mL and the median Gleason 3+4. Ninety-two lesions (43 lymph nodes and 49 prostate lesions) were analyzed, including 63 malignant lesions. In early dynamic acquisitions, the maximum SUV was significantly higher, respectively on mCT and GE-LS, in positive lymph nodes (P < 0.001, P = 0.007) and prostate (P = 0.001, P = 0.02). ROC curves showed for lymph nodes acquired on mCT, a trend to better numbers of sensitivity and specificity for early acquisitions, compared with late acquisitions. Conclusion. - Assessment of lymph nodes and prostate pathological status with early dynamic curves PET/CT FCH was interestingly possible in a disease where proofs of malignancy are difficult to obtain. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:138 / 147
页数:10
相关论文
共 50 条
  • [1] Assessment of lymph nodes and prostate status using early dynamic curves with F-18-Choline PET/CT in prostate cancer
    Mathieu, Cedric
    Ferrer, Ludovic
    Carlier, Thomas
    Colombie, Mathilde
    Rusu, Daniela
    Kraeber-Bodere, Frangoise
    Campion, Loic
    Rousseau, Caroline
    FRONTIERS IN MEDICINE, 2015, 2
  • [2] Diagnostic performance of 18F-choline PET-CT in prostate cancer
    Samper Ots, P.
    Luis Cardo, A.
    Vallejo Ocana, C.
    Cabeza Rodriguez, M. A.
    Glaria Enriquez, L. A.
    Couselo Paniagua, M. L.
    Olivera Vegas, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (06): : 766 - 773
  • [3] Pitfalls with 18F-Choline PET/CT in patients with prostate cancer
    Garcia Vicente, A. M.
    Nunez Garcia, A.
    Soriano Castrejon, A. M.
    Jimenez Londono, G. A.
    Cordero Garcia, J. M.
    Palomar Munoz, A.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2013, 32 (01): : 37 - 39
  • [4] Comparison of choline influx from dynamic 18F-Choline PET/CT and clinicopathological parameters in prostate cancer initial assessment
    Palard-Novello, Xavier
    Blin, Anne-Lise
    Bourhis, David
    Garin, Etienne
    Salaun, Pierre-Yves
    Devillers, Anne
    Querellou, Solene
    Bourguet, Patrick
    Le Jeune, Florence
    Saint-Jalmes, Herve
    ANNALS OF NUCLEAR MEDICINE, 2018, 32 (04) : 281 - 287
  • [5] Comparison of choline influx from dynamic 18F-Choline PET/CT and clinicopathological parameters in prostate cancer initial assessment
    Xavier Palard-Novello
    Anne-Lise Blin
    David Bourhis
    Etienne Garin
    Pierre-Yves Salaün
    Anne Devillers
    Solène Querellou
    Patrick Bourguet
    Florence Le Jeune
    Hervé Saint-Jalmes
    Annals of Nuclear Medicine, 2018, 32 : 281 - 287
  • [6] Diagnostic performance of 18F-choline PET-CT in prostate cancer
    P. Samper Ots
    A. Luis Cardo
    C. Vallejo Ocaña
    M. A. Cabeza Rodríguez
    L. A. Glaria Enríquez
    M. L. Couselo Paniagua
    J. Olivera Vegas
    Clinical and Translational Oncology, 2019, 21 : 766 - 773
  • [7] Role of 18F-choline PET/CT in evaluation of patients with prostate carcinoma
    Hodolic, Marina
    RADIOLOGY AND ONCOLOGY, 2011, 45 (01) : 17 - 21
  • [8] 18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer
    Quero, Laurent
    Vercellino, Laetitia
    de Kerviler, Eric
    Mongiat-Artus, Pierre
    Culine, Stephane
    Merlet, Pascal
    Ravery, Vincent
    Meria, Paul
    Desgrandchamps, Francois
    Hennequin, Christophe
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) : e492 - e495
  • [9] Comparison of 18F-Choline PET/CT and MRI functional parameters in prostate cancer
    Palard-Novello, Xavier
    Beuzit, Luc
    Gambarota, Giulio
    Le Jeune, Florence
    Garin, Etienne
    Salaun, Pierre-Yves
    Devillers, Anne
    Querellou, Solene
    Bourguet, Patrick
    Saint-Jalmes, Herve
    ANNALS OF NUCLEAR MEDICINE, 2019, 33 (01) : 47 - 54
  • [10] Comparison of 18F-Choline PET/CT and MRI functional parameters in prostate cancer
    Xavier Palard-Novello
    Luc Beuzit
    Giulio Gambarota
    Florence Le Jeune
    Etienne Garin
    Pierre-Yves Salaün
    Anne Devillers
    Solène Querellou
    Patrick Bourguet
    Hervé Saint-Jalmes
    Annals of Nuclear Medicine, 2019, 33 : 47 - 54